Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1469 Vaccine for Ebola-Bundibugyo Virus Disease Prevention
NCT07737717Phase 1Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mRNA-1469 in Ebola virus disease (EVD) (6 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions at Day 7, Number of Participants with Unsolicited Adverse Events at Day 28 and 2 more. Started Jul 2026; status: active, not recruiting.
02
Drugs
mRNA-1469
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT07737717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07737717.